Resverlogix Corp. (TSE:RVX – Get Free Report)’s stock price reached a new 52-week low on Monday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 1445 shares trading hands. The stock had previously closed at C$0.05.
Resverlogix Stock Performance
The stock has a market cap of C$7.92 million, a P/E ratio of -1.98 and a beta of 0.71. The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04. The stock has a 50-day simple moving average of C$0.05 and a 200-day simple moving average of C$0.06.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Featured Stories
- Five stocks we like better than Resverlogix
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Health Care Stocks Explained: Why You Might Want to Invest
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Stock Market Sectors: What Are They and How Many Are There?
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
